April 24 (Reuters) - ARGENX NV:
* REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING
* EIGHT-WEEK FOLLOW-UP DATA SHOW SEPARATION OF CLINICAL EFFICACY SCORES BETWEEN TREATMENT GROUP AND PLACEBO GROUP THROUGH DURATION OF STUDY
* TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
